devices that integrate glp-1 schedules and glucose data GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal? Automated Insulin Delivery's Role in

Semaglutide was the most cost-effective treatment compared to exenatide, dulaglutide, liraglutide, or no treatment in short-term analyses (approximately one and a half years) that assessed quality-adjusted life years and incremental cost-effectiveness ratios [135144]

Best for: BMI 27-35 seeking a non-surgical jumpstart

As one of the fastest-growing pharmaceutical markets, GLP-1 therapies are forecasted to exceed $100 billion by 2030

10.2147/vhrm.s3374 123 MistryG

The shift toward home delivery models further supports adherence and market expansion

Gastroparesis (Stomach Paralysis): In severe cases, the stomach slows down so much that it effectively stops moving food forward